CHUGAI PHARMACEUTICAL CO.,LTD. [4519.T]
TOKYO, Mar 31 (Pulse News Wire) – Chugai Pharmaceutical CO.,LTD. (4519.T) reported its shareholding structure as of December 31, 2025.
Roche Holding Ltd. remains the controlling shareholder with 61.12% voting rights. The companies entered into a strategic alliance agreement in October 2002, which includes exclusive development and sales rights for certain markets. Under the agreement, Roche holds the primary selection rights for overseas development and sales of Chugai's drug candidates outside Japan, South Korea, and Taiwan. Additionally, Chugai maintains operational independence while ensuring stable revenue through Roche’s global distribution network.
Key agreements also stipulate that Roche must retain at least 50% of Chugai's outstanding shares and cannot sell to competitors without prior board approval. Chugai retains preemptive purchase rights during Roche's stock disposal. As of March 31, 2026, three directors appointed by Roche continue to serve on Chugai's board, contributing to global oversight and guidance. Chugai ensures minority shareholders' interests by establishing a special committee comprising independent external directors to review significant transactions with Roche. This committee evaluates the necessity, fairness, and conditions of such transactions to protect minority shareholders’ benefits.
🟢 Confidence: High AI-translated content.